CONTACT
+91 80 2808 2808
info@biocon.com
About Us
Overview
Who we are
Our Key Priorities
Board of Directors
Key Management Team
Our Legacy
Fact Sheet
Our Stories
Scientific Publications
Awards & Recognition
Products
Overview
Key Therapeutic Areas
Generics
Biosimilars
Novel Biologics
Branded Formulations
Businesses
Overview
Generics
Executive Leadership Team
API
Generic Formulations
Quality & Compliance
Manufacturing Operations
Research & Development
Regulatory Affairs
Biosimilars
Biocon Biologics
Board of Directors
Executive Leadership Team
Global Portfolio
Wide Global Footprint
Quality & Compliance
Partners
Global Scale Manufacturing
Research & Development
Branded Formulations
Novel Biologics
Biocon and Novels
Novels Pipeline
Research Services
Investors
Overview
Financial Fact Sheet
Financial Information
Annual Reports
Quarterly Reports
Key Figures (Annual & Quarterly)
Earnings Call Recordings
Earnings Call Transcripts
Subsidiary Financials
Investor Presentations
Corporate Governance
Overview
Board of Directors
Board Committees
Our Leadership
Corporate Structure
Company History & Milestones
Governance Documents & Policies
Share Information
Share Graph
Share Series
Share Price Look Up
Investment Calculator
Share Price Alerts
Fragulizer
Dividends
Unclaimed and Unpaid Dividend
IEPF
Shareholder Services
Annual General Meeting
Postal Ballot
Investor Feedback
Investor FAQ
Miscellaneous Communication
Financial Calendar
Stock Exchange Disclosures
Notice of Board Meeting
Investors Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements & Disclosures
Analyst Coverage
Code Of Conduct
Email Subscription Services
Investor Contact
Disclosures under Regulation 46 of LODR
Careers
Overview
Working With Us
Now Hiring
Functions
Our Culture
Diversity And Inclusion
Learning & Development
Awards & Recognition
Benefits
Meet Our Employees
Career FAQ’s
Responsibility
Overview
Biocon Foundation
Social Impact
Partners
Grant-in-Aid
Awards and Recognition
Sustainability
Safer Workplace
An Environment of Change
Environmental Clearance
EHS Certifications
Biocon Academy
News
Overview
Press Releases
Company Statements
Media Stories
Image Gallery
Video Gallery
Events & Calendar
Media Contacts
Resource Center
More+
Contact Us
Blog
For Patients
Biocon in Malaysia
Group Companies
Syngene
Biocon BIologics
Bicara
Biocon Academy
Company Statements 2023
Biocon
/
News – Posts
/
Company Statements
/
Company Statements 2023
Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept
Mon, 13-Nov-2023
Posted by: BIOCON
No Comments
Update on U.S. FDA Inspection at Biocon Biologics’ Manufacturing Facility in Johor, Malaysia
Wed, 18-Oct-2023
Posted by: BIOCON
No Comments
Biocon Biologics Receives Complete Response Letter from US FDA for Biosimilar Insulin Aspart
Sat, 07-Oct-2023
Posted by: BIOCON
No Comments
Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept
Wed, 20-Sep-2023
Posted by: BIOCON
No Comments
U.S. FDA Completes Two cGMP Inspections at Biocon Biologics Insulins Facility in Malaysia
Fri, 21-Jul-2023
Posted by: BIOCON
No Comments
Biocon’s API manufacturing facility in Bangalore receives EU GMP compliance certificate
Thu, 08-Jun-2023
Posted by: BIOCON
No Comments
Biocon Pharma Limited’s facility at Bengaluru Concludes USFDA Surveillance and Inspection, With Zero Observations
Sat, 03-Jun-2023
Posted by: BIOCON
No Comments
Biocon’s API facility at Hyderabad Concludes USFDA Inspection, with Zero Observations
Sat, 20-May-2023
Posted by: BIOCON
No Comments
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
Fri, 28-Apr-2023
Posted by: BIOCON
No Comments
USFDA issues a CRL for the Biologics License Application for Bevacizumab
Sun, 12-Feb-2023
Posted by: BIOCON
No Comments
1
2
